Pefloxacin - description of the drug, instructions for use, reviews

Write a review

Reviews: 0

Manufacturers: Grodzisk Pharmaceutical Works Polfa Co. (Poland)

Active ingredients

• Pefloxacin

Disease class

• Bacterial meningitis, not elsewhere classified
• Acute and subacute endocarditis
• Acute upper respiratory tract infection of multiple and unspecified localization
• Acute lower respiratory tract respiratory infection, unspecified
• Cholecystitis
• Pyogenic arthritis
• Osteomyelitis
• Bacterial intestinal infection, unspecified
• Diarrhea and gastroenteritis of suspected infectious origin
• Septicemia, unspecified
• Urinary tract infection without established localization
• Inflammatory disease of the prostate, unspecified
• Inflammatory diseases of the male genital organs, not elsewhere classified
• Inflammatory diseases of the female pelvic organs, unspecified

Clinical and pharmacological group

• Not indicated. See instructions

Pharmacological action

• Antibacterial
• Bactericidal

Pharmacological group

• Quinolones/fluoroquinolones

pharmachologic effect

Antimicrobial medication. The active substance belongs to the group of fluoroquinolones . The principle of antimicrobial action is based on the ability of the active component to block DNA gyrase, to prevent the replication of the A-subunit of RNA, DNA, and to disrupt the synthesis of bacterial proteins.

Has a wide spectrum of anti- and anti-microbial effects. For gram-positive microorganisms, the antimicrobial effect appears only on cells that are in the process of mitosis.

In relation to gram-negative bacteria - into cells that are in the stage of division and in the stage of rest. The active substance is resistant to beta-lactamases.

Release form and composition

• Film-coated tablets: round, biconvex, white (a yellowish tint is possible) (10 pcs. in strip packs, 1-2 packs in a cardboard pack);
• Solution for infusion: transparent, yellowish in color (a greenish tint is possible) (5 ml in ampoules, 5 or 10 ampoules in a cardboard pack).

Active substance – pefloxacin mesylate:

• 1 tablet – 200 or 400 mg;
• 1 ml of solution – 80 mg.

Additional components of the tablets:

• Excipients: potato or corn starch, microcrystalline cellulose, lactose, polyvinylpyrrolidone, talc, calcium stearate;
• Shell: Polyethylene oxide 4000, 1,2-propylene glycol, titanium dioxide, hydroxypropyl cellulose, talc or Opadry.

Auxiliary components of the solution: sodium pyrosulfite, benzyl alcohol, sodium carbonate, disodium salt of ethylenediaminetetraacetic acid, ascorbic acid, water for injection.

Pharmacodynamics and pharmacokinetics

The antimicrobial agent is quickly absorbed from the lumen of the digestive tract after taking the tablet orally. 20 minutes after a single use of 400 mg of Pefloxacin, about 90% of the dose taken is absorbed, and the Cmax is 4 mcg/ml and is achieved in 1.5-2 hours.

After intravenous infusion, Cmax is achieved faster - after 1 hour. After repeated use, the concentration of the active antimicrobial substance in the bronchial mucosa is 5 μg/ml.

Pefloxacin is capable of binding to plasma proteins by 25-30%. The active ingredient penetrates well into all tissues in the body and fluids:

• sputum;
• heart;
• bronchial secretion;
• cerebrospinal fluid;
• bile;
• bone;
• lungs;
• peritoneal fluid;
• prostate.

In the above tissues and fluids, the concentration of the antimicrobial substance is higher than in the blood.

After 3 doses of 400 mg, the concentration of Pefloxacin in the cerebrospinal fluid is 4.5 mcg/ml; when the dose is doubled, this figure reaches 9.8 μg/ml, and the ratio between the concentrations of the antibiotic in plasma and liquid is 89%.

Metabolism occurs in the hepatic system, where the active substance, as a result of methylation, is converted to dimethylpefloxacin, whose antibacterial activity is much more pronounced than that of its predecessor.

The metabolite is able to oxidize to N-oxide, and then conjugate with glucuronic acid to form pefloxacin glucuronide.

When taken orally, the T1\2 indicator is 8-10 hours, and when used repeatedly - 12-13 hours. After a single intravenous infusion, T1\2 is 7.2-13 hours, and with repeated administration - 14-15 hours. It is excreted partially in the form of metabolites, as well as unchanged in feces and urine (60%) through the renal system.

After a single use of the drug, its metabolites can be detected in the urine for 84 hours. During hemodialysis, the extraction coefficient of the active substance is 23%.

Concentrate for the preparation of solution for infusion Pefloxacin-AKOS (Pefloxacin-AKOS)

Instructions for medical use of the drug

Description of pharmacological action

Has a wide spectrum of action. Active against gram-negative bacteria Escherichia coli, Klebsiella spp., indole-positive and indole-negative Proteus spp., incl. Proteus mirabilis, Enterobacter spp., Morganella morganii, Yersinia enterocolitica, Vibrio cholerae, Vibrio parahaemolyticus, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Pseudomonas aeruginosa, Moraxella catarrhalis, Pasteurella multocida, Campylobacter spp., Serratia spp., Citro bacter spp., Salmonella spp., Shigella spp., Haemophilus spp. Aerobic gram-positive bacteria - Staphylococcus spp. (including those producing and not producing penicillinase and methicillin-resistant), Streptococcus spp., incl. Streptococcus pyogenes, Streptococcus agalactiae, Corynebacterium diphtheriae, Listeria monocytogenes, intracellular bacteria: Legionella pneumophila, Brucella spp., Chlamydia spp., as well as bacteria that produce beta-lactamases. Suppresses the vital activity of Mycoplasma spp., Helicobacter. Moderately sensitive - Pneumococcus, Acinetobacter spp., Pseudomonas spp. Resistant - gram-negative anaerobes, Treponema spp., Mycobacterium tuberculosis. In relation to gram-negative strains, it is effective on both dividing cells and cells in the resting stage; in the case of gram-positive strains - only on cells in the process of mitotic division.

Indications for use

Infectious and inflammatory diseases caused by microorganisms sensitive to pefloxacin: kidney and urinary tract infections; Gastrointestinal tract (including salmonellosis, typhoid fever); mouth, teeth, jaws; infections of the gallbladder and biliary tract (cholecystitis, cholangitis, empyema of the gallbladder); infections of the pelvic organs (including adnexitis and prostatitis); bones, joints, skin and soft tissues, infections of the lower respiratory tract and ENT organs (middle ear, paranasal sinuses, pharynx, larynx); eye infections; intra-abdominal abscesses, peritonitis, sepsis, septicemia; endocarditis; meningoencephalitis; osteomyelitis; gonorrhea, chlamydia, epididymitis, chancroid; surgical and nosocomial infections; prevention of surgical infection.

Release form

Concentrate for the preparation of solution for infusion 80 mg/ml; dark glass ampoule 5 ml with ampoule knife cardboard pack 10; Concentrate for the preparation of solution for infusion 80 mg/ml; dark glass ampoule 5 ml with ampoule knife contour cell packaging 5 cardboard pack 1; Concentrate for the preparation of solution for infusion 80 mg/ml; dark glass ampoule 5 ml with ampoule knife contour cell packaging 5 cardboard pack 2;

Pharmacodynamics

Inhibits DNA gyrase, replication of the A-subunit of DNA, RNA, disrupts the synthesis of bacterial proteins, and has a bactericidal effect. Gram-negative strains are sensitive to the action of pefloxacin both at the stage of cell division and at the resting stage; gram-positive - only during mitotic division. Active against most aerobic gram-negative bacteria - Escherichia coli, Klebsiella spp., indole-positive and indole-negative Proteus spp., incl. Proteus mirabilis, Enterobacter spp., Morganella morganii, Yersinia enterocolitica, Vibrio cholerae, Vibrio parahaemolyticus, Neisseria gonorrhoeae, Neisseria meningitidis, Haemophilus influenzae, Pseudomonas aeruginosa, Moraxella catarrhalis, Pasteurella multocida, Campylobacter spp., Serratia spp., Citro bacter spp., Salmonella spp., Shigella spp., Haemophilus spp., in relation to aerobic gram-positive bacteria - Staphylococcus spp. (including those producing and not producing penicillinase and methicillin-resistant), Streptococcus spp., incl. Streptococcus pyogenes, Streptococcus agalactiae, Corynebacterium diphtheriae, Listeria monocytogenes, against intracellular bacteria: Legionella pneumophila, Brucella spp., Chlamydia spp., as well as against bacteria that produce beta-lactamases. Suppresses the vital activity of Mycoplasma spp., Helicobacter. Moderately sensitive - Pneumococcus, Acinetobacter spp., Clostridium perfringens, Pseudomonas spp., Chlamydophila (Chlamydia) trachomatis. Resistant - gram-negative anaerobes, Treponema spp., Mycobacterium tuberculosis. For diseases caused by moderately sensitive microorganisms, in vitro sensitivity studies are required.

Pharmacokinetics

With intravenous administration - within 60 minutes. The therapeutic concentration is maintained for 12–15 hours. After repeated administration, Cmax in the blood is 10 mcg/ml; concentration in the bronchial mucosa - 5 mcg/ml; binding to plasma proteins is 25–30%. Penetrates well into body tissues and fluids, incl. into bronchial secretions, lungs, prostate gland, cerebrospinal fluid and bone tissue. The volume of distribution when taken orally is 1.5–1.8 l/kg, the concentration in the cerebrospinal fluid after 3 doses of 400 mg is 4.5 mcg/ml, when the dose is increased to 800 mg — 9.8 mcg/ml; the ratio between plasma and liquid concentrations is 89%. Concentration in other organs and tissues 12 hours after the last dose: thyroid gland - 11.4 mcg/g, salivary glands - 2.2 mcg/g, skin - 7.6 mcg/g, nasopharyngeal mucosa - 6 mcg/g, tonsils - 9 mcg/g, muscles - 5.6 mcg/g. Metabolized in the liver by methylation to dimethylpefloxacin (has significant antibacterial activity), oxidized to N-oxide and conjugated with glucuronic acid to form pefloxacin glucuronide. With intravenous administration, T1/2 after one administered dose is 7.2–13 hours, after repeated administrations - 14–15 hours, with repeated administration - 12–13 hours. It is excreted unchanged and in the form of metabolites by the kidneys (50– 60%) and found in feces (30%). The content of unchanged drug in the urine 1–2 hours after administration is 25 mcg/ml, after 12–24 hours — 15 mcg/ml. Unchanged pefloxacin and its metabolites are detected in the urine within 84 hours after the last administration. Poorly amenable to dialysis (extraction coefficient - 23%).

Use during pregnancy

Contraindicated during pregnancy. Breastfeeding should be stopped during treatment.

Contraindications for use

Hypersensitivity, epilepsy, hemolytic anemia, glucose-6-phosphate dehydrogenase deficiency, pregnancy, lactation, children (up to 18 years). With caution - atherosclerosis of cerebral vessels, cerebrovascular accident, organic lesions of the central nervous system, convulsive syndrome of unknown etiology.

Side effects

From the nervous system and sensory organs: depression, headache, dizziness, increased fatigue, insomnia, increased convulsive readiness, anxiety, agitation, tremor, rarely - convulsions. From the gastrointestinal tract: nausea, vomiting, diarrhea, abdominal pain, anorexia, flatulence, pseudomembranous colitis, transient increase in liver transaminases, cholestatic jaundice, hepatitis, liver necrosis. From the genitourinary system: crystalluria, rarely - glomerulonephritis, dysuria. Allergic reactions: skin rash, itching, urticaria, skin hyperemia, photosensitivity, rarely - Quincke's edema, bronchospasm, arthralgia. From the hematopoietic system: leukopenia, neutropenia. thrombocytopenia (at doses of 1600 mg/day), agranulocytosis, eosinophilia. Other: tachycardia, myalgia, tendonitis, tendon rupture, candidiasis.

Directions for use and doses

IV drip (for infective endocarditis, sepsis, osteomyelitis, for severe infections), 1st dose - 800 mg; then - 400 mg every 12 hours. The infusion is carried out for 1 hour; The contents of the ampoule are dissolved in 250 ml of 5% glucose solution. The course of treatment is 1–2 weeks (no more). In case of liver dysfunction, correction of the dosage regimen is necessary: ​​for minor disorders, the drug is prescribed at a dose of 400 mg/day, for more severe disorders - every 36 hours, for severe liver pathology, the interval between doses is increased to 2 days. The course of treatment is no more than 30 days. For patients with impaired renal function (with creatinine Cl below 20 ml/min), a single dose is 50% of the average (with a dosage frequency of 2 times a day) or a full single dose 1 time a day. For elderly people, the dose of the drug is reduced by 1/3.

Overdose

Treatment: symptomatic therapy, if necessary - hemodialysis and peritoneal dialysis. A specific antidote is unknown.

Interactions with other drugs

Pefloxacin reduces the metabolism of theophylline in the liver, which leads to increased concentrations of theophylline in plasma and the central nervous system (the dose of theophylline should be reduced). Cimetidine and other microsomal oxidation inhibitors increase T1/2, reduce total clearance, but do not affect the volume of distribution and renal clearance. Coating agents slow down absorption. The simultaneous use of beta-lactam antibiotics helps prevent the development of resistance during the treatment of staphylococcal infections. Aminoglycosides, piperacillin, azlocillin, ceftazidime enhance the antibacterial effect (including for infections caused by Pseudomonas aeruginosa). Drugs that block tubular secretion slow down the elimination of pefloxacin.

Precautions for use

The drug significantly reduces the prothrombin index (in patients taking indirect anticoagulants, constant monitoring of the blood picture is necessary). In case of renal and liver failure, it is necessary to reduce the single dose and frequency of administration in accordance with the degree of damage to liver or kidney function. If severe and prolonged diarrhea occurs during or after treatment, it is necessary to exclude the development of pseudomembranous colitis. If the diagnosis is confirmed, immediate discontinuation of the drug and administration of appropriate treatment is required.

Special instructions for use

During the treatment period it is necessary to drink plenty of fluids. Contact with direct sunlight should be avoided. During the treatment period, you should refrain from engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Storage conditions

List B.: In a place protected from light, at a temperature of 15–25 °C.

Best before date

24 months

ATX classification:

J Antimicrobials for systemic use

J01 Antimicrobials for systemic use

J01M Antibacterial drugs - quinolone derivatives

J01MA Fluoroquinolones

J01MA03 Pefloxacin

Indications for use

Pefloxacin is prescribed for infectious lesions caused by a microorganism sensitive to the antibiotic:

• soft tissue diseases;
• typhoid fever;
• salmonellosis;
• empyema of the gallbladder;
• prostatitis;
• adnexitis;
• cholangitis;
• nosocomial infections;
• chlamydia;
• gonorrhea;
• cholecystitis;
• intra-abdominal abscesses;
• skin diseases;
• eye infections;
• endocarditis;
• sepsis;
• peritonitis;
• diseases of joints and bones;
• surgical infections;
• epididymitis;
• lesions of the paranasal sinuses;
• osteomyelitis;
• middle ear lesions;
• chancroid ; _
• diseases of the ENT organs;
• respiratory tract infections;
• lesions of the larynx, pharynx.

The drug can be used to prevent infectious diseases after surgical interventions.

Instructions:

Clinical and pharmacological group

06.038 (Antibacterial drug of the fluoroquinolone group)

pharmachologic effect

Antimicrobial agent of the fluoroquinolone group with a broad spectrum of action. It has a bactericidal effect, inhibiting the replication of bacterial DNA at the level of DNA gyrase, and also has an effect on RNA and the synthesis of bacterial proteins.

It acts on gram-negative bacteria that are both in the division stage (growth phase) and in the resting stage. For gram-positive strains, it only affects cells in the process of mitotic division. Shows activity against intracellular pathogens.

Active against gram-positive bacteria: Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus; gram-negative bacteria: Escherichia coli, Klebsiella spp., Enterobacter spp., Serratia spp., Proteus mirabilis, Proteus vulgaris, Citrobacter spp., Salmonella spp., Shigella spp., Haemophilus ducreyi, Haemophilus influenzae, Neisseria gonorrhoeae, Neisseria meningitidis, Aeromonas spp. ., Campylobacter spp., Legionella spp., Moraxella spp., Morganella spp., Pasteurella spp., Providencia spp., Pseudomonas aeruginosa, Yersinia spp., Ureaplasma urealyticum.

The following are moderately sensitive to pefloxacin: Acinetobacter spp., Gardnerella vaginalis, Mycoplasma spp., Chlamydia spp; slightly sensitive: Streptococcus spp. (including Streptococcus pneumoniae), Enterococcus spp.

Pharmacokinetics

After a single infusion of 400 mg, the Cmax of pefloxacin is 4 mcg/ml and is maintained for 12-15 hours. After IV infusion, the pharmacokinetic parameters are the same as after oral administration. The AUC for both routes of administration is the same, indicating complete absorption of pefloxacin.

After oral administration, pefloxacin is rapidly absorbed from the gastrointestinal tract. After a single oral dose of 400 mg of pefloxacin, 90% of the dose is absorbed after 20 minutes, while Cmax is reached after 1-2 hours and is 4 mcg/ml after 1.5 hours. Bioavailability – about 100%.

Plasma protein binding is 25-30%. Vd - 1.5-1.8 l/kg. Pefloxacin quickly penetrates into tissues, organs and body fluids (aortic valves, mitral valve, heart muscle, bones, abdominal cavity, peritoneal fluid, gall bladder, prostate gland, saliva, sputum, pancreatic tissue /including necrotic tissue/) . The concentration of pefloxacin in the listed fluids and tissues is higher than the concentration in blood plasma.

T1/2 is approximately 8-10 hours, with repeated administration - 12-13 hours. It is excreted mainly in the urine (60% within 72 hours). 30% is excreted unchanged in the bile, partly in the form of metabolites: norfloxacin, pefloxacin-N-oxide and pefloxacin glucuronide. The content of unchanged pefloxacin in the urine 1-2 hours after administration is 25 mcg/ml, after 12-24 hours – 15 mcg/ml. Unchanged pefloxacin and its metabolites are detected in the urine within 84 hours after the last dose of the drug. The extraction coefficient of pefloxacin during hemodialysis is 23%.

Dosage

They are set individually, depending on the location and severity of the infection, as well as the sensitivity of the microorganism.

When taken orally, the average dose is 800 mg/day in 2 divided doses.

For severe infections, it is administered intravenously: the first dose is 800 mg, then 400 mg every 12 hours. For mild renal dysfunction, 400 mg is administered every 24 hours, for more severe disorders - every 36 hours.

For patients with liver diseases with intravenous drip administration, a single dose is 8 mg/kg; duration of infusion - 1 hour. The frequency of infusions is once every 24 hours in patients with jaundice; in patients with ascites - once every 36 hours; in patients with jaundice and ascites - once every 48 hours.

The maximum daily dose is 1.2 g/day.

Drug interactions

With the simultaneous use of pefloxacin and aminoglycosides, synergism is observed against Pseudomonas aeruginosa; with indirect anticoagulants - their effect may be enhanced.

The absorption of pefloxacin is slowed down when taken simultaneously with antacids containing aluminum hydroxide and magnesium hydroxide.

Concomitant use of pefloxacin and cimetidine leads to a decrease in total clearance and an increase in T1/2 of pefloxacin.

Pefloxacin inhibits microsomal oxidation in liver cells by affecting enzymes of the cytochrome P450 system. Therefore, pefloxacin slows down the metabolism of theophylline in the liver, which leads to increased plasma theophylline concentrations.

Pefloxacin should not be mixed with solutions containing chlorine ions to avoid precipitation.

Use during pregnancy and lactation

Pefloxacin is contraindicated for use during pregnancy and lactation (breastfeeding).

Experimental studies have established the toxic effects of monofluoroquinolones on cartilage tissue.

Side effects

From the digestive system: nausea, vomiting, diarrhea, abdominal pain.

From the side of the central nervous system: headache, insomnia.

From the musculoskeletal system: myalgia, arthralgia.

From the hematopoietic system: thrombocytopenia (when used at a dose of 1.6 g/day).

Dermatological reactions: photosensitivity.

Allergic reactions: skin itching, urticaria.

Indications

Treatment of infectious and inflammatory diseases caused by microorganisms sensitive to pefloxacin: infections of the liver and biliary tract; sepsis and bacterial endocarditis; staphylococcal meningitis and meningitis caused by gram-negative flora; bone and joint infections; lower respiratory tract infections; ENT infections; urinary tract infections; abdominal infections; gynecological infections; skin and soft tissue infections; sexually transmitted diseases.

Treatment and prevention of infectious complications after surgical interventions.

Contraindications

Glucose-6-phosphate dehydrogenase deficiency, pregnancy, lactation (breastfeeding), childhood and adolescence up to 15 years, hypersensitivity to pefloxacin and other fluoroquinolones.

special instructions

Use with caution in patients with cerebral atherosclerosis, cerebral circulatory disorders, epilepsy, convulsive syndrome of unknown etiology, and severe liver dysfunction.

During treatment, ultraviolet radiation should be avoided.

It is possible to combine pefloxacin with beta-lactam antibiotics and rifampicin to prevent the development of bacterial resistance to the latter.

Medicines containing PEFLOXACIN

• PEFLOXACIN-AKOS conc. d/prep. r-ra d/inf. 400 mg/5 ml: amp. 5 or 10 pcs. • PEFLOXACIN-AKOS tab., coated. film coating, 400 mg: 10 or 20 pcs. • ABACTAL® (ABAKTAL) concentrate for preparation. solution for intravenous administration 400 mg/5 ml: amp. 10 pieces. • UNIKPEF® (UNIKPEF®) solution for inf. 400 mg/100 ml: vial. 1 PC. • PEFLOXABOL solution for inf. 400 mg/100 ml: vial. 1 PC. • ABACTAL® (ABAKTAL) tab., coated. coated, 400 mg: 10 pcs. • PEFLOXACIN solution for inf. 400 mg/100 ml: bottle. or 48 pcs. • PELOX-400 (PELOX-400) tab., coated. coated, 400 mg: 10 pcs. • UNIKPEF® tab., coated. film-coated, 400 mg: 20 or 100 pcs. • PEFLOXABOL conc. d/prep. r-ra d/inf. 400 mg/5 ml: amp. 5 or 10 pcs. • PEFLOXACIN-AKOS tab., coated. film coating, 200 mg: 10 or 20 pcs.

Contraindications

• hemolytic anemia;
• period of gestation ;
• individual intolerance to fluoroquinolones;
• glucose-6-phosphate dehydrogenase deficiency;
• breast-feeding;
• epilepsy;
• Manufacturer's age limit is up to 18 years.

Relative contraindications:

• convulsive syndrome , the etiology of which is unknown;
• pathology of blood circulation in the brain;
• organic changes/lesions of the central nervous system;
• atherosclerosis of the vessels of the head.

Side effects

Nervous system:

• convulsions (rarely recorded);
• migraine type headaches;
• fast fatiguability;
• anxiety;
• limb tremors;
• emotional arousal;
• dizziness;
• depression.

Digestive tract:

• cholestatic jaundice;
• abdominal pain;
• diarrhea syndrome;
• increased levels of ALT, AST;
• pseudomembranous colitis;
• flatulence;
• vomit;
• hepatic necrosis;
• nausea;
• hepatitis.

Urinary tract:

• glomerulonephritis (rarely reported);
• crystalluria;
• dysuria.

Other reactions:

• phlebitis (injection forms);
• Quincke's edema;
• eosinophilia;
• neutropenia;
• skin itching;
• candidiasis;
• arthralgia;
• leukopenia;
• myalgia;
• tachycardia;
• tendon rupture;
• tendinitis;
• photosensitivity;
• hyperemia of the skin;
• skin rashes;
• bronchospasm.

Instructions for use of Pefloxacin (Method and dosage)

The treatment regimen and the selection of a single dose of Pefloxacin are carried out on an individual basis, taking into account concomitant pathology, the severity of the infectious disease, the localization of the inflammatory process, and the sensitivity of the flora.

Instructions for the use of Pefloxacin for uncomplicated infectious diseases : 400 mg twice a day (the average daily dosage is 800 mg of pefloxacin). The tablets must not be chewed. It is recommended to drink plenty of liquid. It is preferable to take on an empty stomach.

For severe infectious diseases, the medication is administered intravenously by drip, having previously dissolved the medication in a 5% glucose solution (250 ml). Initially, a single dose of 800 mg is administered, then 400 mg every 12 hours. The duration of antimicrobial therapy should not exceed 1-2 weeks.

In case of pathology of the hepatic system, the treatment regimen is adjusted. For uncomplicated diseases, 400 mg is prescribed twice a day; for severe infectious lesions - 400 mg every 36 hours. The interval between antibiotic uses for severe lesions of the hepatic system is up to 2 days. The duration of antimicrobial therapy is no more than 30 days.

In case of pathology of the renal system, only 50% of the intended dose can be administered once. Elderly patients are prescribed 2/3 of the expected dose.

Similar drugs:

• Augmentin Oral tablets
• Tea tree DN Ointment for external use
• Augmentin Powder for suspension for oral administration
• Bactrim Oral suspension
• Dioxydin Mouth rinse solution
• Pancef Oral tablets
• Nifuroxazide (Nifuroxazide) Oral tablets
• Cifran OD Oral tablets
• Pancef Granules for the preparation of suspension for oral administration
• Augmentin ES Powder for oral solution

** The Drug Directory is intended for informational purposes only. For more complete information, please refer to the manufacturer's instructions. Do not self-medicate; Before starting to use Pefloxacin, you should consult a doctor. EUROLAB is not responsible for the consequences caused by the use of information posted on the portal. Any information on the site does not replace medical advice and cannot serve as a guarantee of the positive effect of the drug.

Are you interested in the drug Pefloxacin? Do you want to know more detailed information or do you need a doctor's examination? Or do you need an inspection? You can make an appointment with a doctor - the Euro lab is always at your service! The best doctors will examine you, advise you, provide the necessary assistance and make a diagnosis. You can also call a doctor at home . Euro lab clinic is open for you around the clock.

** Attention! The information presented in this medication guide is intended for medical professionals and should not be used as a basis for self-medication. The description of the drug Pefloxacin is provided for informational purposes and is not intended for prescribing treatment without the participation of a doctor. Patients need to consult a specialist!

If you are interested in any other drugs and medications, their descriptions and instructions for use, information about the composition and form of release, indications for use and side effects, methods of use, prices and reviews of drugs, or you have any other questions and suggestions - write to us, we will definitely try to help you.

Interaction

In the treatment of staphylococcal infectious diseases, the combination of Pefloxacin with beta-lactam antibacterial agents helps prevent the development of resistance.

Antibacterial synergism is observed with simultaneous therapy with Azlocillin, Piperacillin, Aminoglycosides, Ceftazidime .

This effect is also recorded in relation to diseases caused by Pseudomonas aeruginosa .

A decrease in the prothrombin index is observed with simultaneous treatment with indirect anticoagulant medications, which requires constant monitoring of blood clotting .

Pharmacokinetic interactions

Antacids containing Mg and/or Al hydroxide interfere with the absorption of the antibacterial component of the drug. The elimination of the active substance is slowed down when treated with medications that can block tubular secretion.

The drug slows down the metabolism of Theophylline in the hepatic system, which may lead to an increase in its concentration in the central nervous system and plasma, which may require adjustment of the treatment regimen.

Cimetidine does not affect renal clearance and volume of distribution, but it can reduce the half-life and total clearance of the antibiotic.

Pharmaceutical interactions

The medication is incompatible with Heparin . Mixing with solutions containing Cl ions is prohibited due to the risk of precipitation.

Pefloxacin

Active substance:

Pefloxacin*

Pharmgroup:

Quinolones/fluoroquinolones

special instructions

For diagnosed mixed infectious lesions of the pelvic and abdominal organs, Pefloxacin is recommended to be prescribed together with other antibiotics active against anaerobic infection ( Clindamycin, Metronidazole ).

Prevention of crystalluria during antibacterial therapy is to drink plenty of fluids. It is recommended to limit exposure to ultraviolet radiation due to possible photosensitization. Severe pathology of the renal system requires an individual approach and selection of a treatment regimen.

If prolonged, severe diarrhea develops, it is necessary to conduct examinations to exclude pseudomembranous colitis . If the diagnosis is reliably confirmed, Pefloxacin is discontinued and syndromic treatment is carried out.

Analogs

Level 4 ATX code matches:
Siflox

Hyleflox

Leflobakt

Lefoccin

Gatifloxacin

Ofloxacin

Faktiv

Tigeron

Lebel

Zanotsin

Lomefloxacin

Eleflox

Lomflox

Tsiprobay

Sparflo

Tariwid

Zoflox

Abaktal

Moxifloxacin

Levofloxacin

• Pelox-400;
• Peflacin;
• Abaktal;
• Peflobid;
• Perflox;
• Perti;
• Unikpef;
• Pefloxacin-Acos;
• Peflacine.